Valeritas (NSDQ:VLRX) today released results from the VERDICT study of its V-Go wearable insulin delivery device, touting improved A1c levels with less insulin.
Data in the study came from a retrospective analysis of 139 patients with type 2 diabetes using the V-Go device, the Bridgewater, N.J.-based company said.
The V-Go device is worn like a patch and delivers a preset basal rate of insulin over the course of 24 hours. The device can also deliver on-demand bolus dosing at mealtimes, Valeritas said.
Results from the trial indicated that patients using the V-Go system had an average reduction in A1c levels of 1.5 and a decrease in insulin total daily dosage of 14%, Valeritas said.
The percent of patients prescribed concomitant medications also decreased, and hypoglycemia decreased from baseline, the company added
“The efficacy and insulin usage results from the Verdict study demonstrate both the medical and economic value of V-Go for patients with type 2 diabetes prescribed insulin. Diabetes has become a major healthcare issue and we have demonstrated through strong, real-world evidence the use of V-Go by patients with type 2 diabetes can reduce not only their A1c levels but also lower their total daily insulin usage,” prez & CEO John Timberlake said in a press release.
Last month, Valeritas said that it inked an exclusive distribution deal with Tritech Biomed to commercialize its V-Go wearable insulin delivery device, designed for patients with Type 2 diabetes, in Israel.
